Canurta CEO updates on audit and U.S. launch
The company learned from delayed public market entry, rebuilt financial reporting, and began initial product sales.
See the latest news and media coverage for Canurta. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-backed multi-target botanical therapies developer
canurta.comLast updated
In short: Canurta advanced its botanical drug pipeline and secured a strategic investment from PharmaDrug Inc. to expand its market presence.
The company learned from delayed public market entry, rebuilt financial reporting, and began initial product sales.
Additionally, Health Canada feedback was positive, a cannabis flavonoid research paper was accepted, and bitcoin payment plans were announced.
The Polykye™ AI Platform accelerates discovery, optimization, and production of multi-target botanical drugs, enabling adaptive medicine.
Cannflavin B reduces tumor cell viability, migration, and invasion in vitro at low concentrations. Findings offer insights into cancer behavior.
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on...
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on...
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on...
MISSISSAUGA, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Canurta Therapeutics (a Canadian Private Controlled Company), based in Mississauga, Ontario, pioneering the development of novel botanical-drugs...
Track Canurta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Canurta and other trending companies.